摘要

Objective: Firm conclusion about whether short and long-term gout medications use has an impact on cancer risk remain inconclusive. The aim of this study was to investigate the association between gout drugs use and risk of cancer. Methods: We conducted a retrospective longitudinal population-based case-control study in Taiwan. Cases were identified all patients who were aged 20 years or above, and had a first time diagnosis of cancers for the period between 2001 and 2011. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated by using conditional logistic regression. Results: We examined 601,733 cases and 2,406,932 matched controls. The adjusted odd ratio for any gout drugs use and overall cancer risk was 1.007 (95% CI: 0.994–1.020). There was a significant risk of leukemia (AOR: 1.34, 95% CI: 1.20–1.50), endometrial cancer (AOR: 1.33, 95% CI: 1.12–1.57), non-Hodgkin's (AOR: 1.24, 95% CI: 1.13–1.35), female breast cancer (AOR: 1.21, 95% CI: 1.13–1.29), cervical cancer (AOR: 1.21, 95% CI: 1.07–1.37). However, no association was observed in male group (AOR: 0.97, 95% CI: 0.95–0.98) but female showed a significantly increased risk of cancer at any site (AOR: 1.107, 95% CI: 1.08–1.13). Conclusion: In summary, our results suggest that gout drugs increase risk of the most common cancers, particularly in leukemia, non-Hodgkin's, endometrial, breast and cervical cancer.
原文英語
期刊Joint Bone Spine
DOIs
出版狀態接受/付印 - 一月 1 2018

指紋

Gout
Case-Control Studies
Odds Ratio
Confidence Intervals
Pharmaceutical Preparations
Neoplasms
Endometrial Neoplasms
Uterine Cervical Neoplasms
Non-Hodgkin's Lymphoma
Leukemia
Breast Neoplasms
Taiwan
Logistic Models

ASJC Scopus subject areas

  • Rheumatology

引用此文

Gout drugs use and risk of cancer : A case-control study. / Yang, Hsuan Chia; Nguyen, Phung Anh Alex; Islam, Mohaimenul; Huang, Chih Wei; Poly, Tahmina Nasrin; Iqbal, Usman; Li, Yu Chuan Jack.

於: Joint Bone Spine, 01.01.2018.

研究成果: 雜誌貢獻文章

@article{ac09ccc48c3e4f0c8e3a1de901a43ec5,
title = "Gout drugs use and risk of cancer: A case-control study",
abstract = "Objective: Firm conclusion about whether short and long-term gout medications use has an impact on cancer risk remain inconclusive. The aim of this study was to investigate the association between gout drugs use and risk of cancer. Methods: We conducted a retrospective longitudinal population-based case-control study in Taiwan. Cases were identified all patients who were aged 20 years or above, and had a first time diagnosis of cancers for the period between 2001 and 2011. Adjusted odds ratios (AORs) and 95{\%} confidence intervals (CIs) were calculated by using conditional logistic regression. Results: We examined 601,733 cases and 2,406,932 matched controls. The adjusted odd ratio for any gout drugs use and overall cancer risk was 1.007 (95{\%} CI: 0.994–1.020). There was a significant risk of leukemia (AOR: 1.34, 95{\%} CI: 1.20–1.50), endometrial cancer (AOR: 1.33, 95{\%} CI: 1.12–1.57), non-Hodgkin's (AOR: 1.24, 95{\%} CI: 1.13–1.35), female breast cancer (AOR: 1.21, 95{\%} CI: 1.13–1.29), cervical cancer (AOR: 1.21, 95{\%} CI: 1.07–1.37). However, no association was observed in male group (AOR: 0.97, 95{\%} CI: 0.95–0.98) but female showed a significantly increased risk of cancer at any site (AOR: 1.107, 95{\%} CI: 1.08–1.13). Conclusion: In summary, our results suggest that gout drugs increase risk of the most common cancers, particularly in leukemia, non-Hodgkin's, endometrial, breast and cervical cancer.",
keywords = "Allopurinol, Breast cancer, Cervical cancer, Gout drugs, Pharmacoepidemiology etc.",
author = "Yang, {Hsuan Chia} and Nguyen, {Phung Anh Alex} and Mohaimenul Islam and Huang, {Chih Wei} and Poly, {Tahmina Nasrin} and Usman Iqbal and Li, {Yu Chuan Jack}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jbspin.2018.01.008",
language = "English",
journal = "Revue du Rhumatisme (English Edition)",
issn = "1169-8446",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Gout drugs use and risk of cancer

T2 - A case-control study

AU - Yang, Hsuan Chia

AU - Nguyen, Phung Anh Alex

AU - Islam, Mohaimenul

AU - Huang, Chih Wei

AU - Poly, Tahmina Nasrin

AU - Iqbal, Usman

AU - Li, Yu Chuan Jack

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: Firm conclusion about whether short and long-term gout medications use has an impact on cancer risk remain inconclusive. The aim of this study was to investigate the association between gout drugs use and risk of cancer. Methods: We conducted a retrospective longitudinal population-based case-control study in Taiwan. Cases were identified all patients who were aged 20 years or above, and had a first time diagnosis of cancers for the period between 2001 and 2011. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated by using conditional logistic regression. Results: We examined 601,733 cases and 2,406,932 matched controls. The adjusted odd ratio for any gout drugs use and overall cancer risk was 1.007 (95% CI: 0.994–1.020). There was a significant risk of leukemia (AOR: 1.34, 95% CI: 1.20–1.50), endometrial cancer (AOR: 1.33, 95% CI: 1.12–1.57), non-Hodgkin's (AOR: 1.24, 95% CI: 1.13–1.35), female breast cancer (AOR: 1.21, 95% CI: 1.13–1.29), cervical cancer (AOR: 1.21, 95% CI: 1.07–1.37). However, no association was observed in male group (AOR: 0.97, 95% CI: 0.95–0.98) but female showed a significantly increased risk of cancer at any site (AOR: 1.107, 95% CI: 1.08–1.13). Conclusion: In summary, our results suggest that gout drugs increase risk of the most common cancers, particularly in leukemia, non-Hodgkin's, endometrial, breast and cervical cancer.

AB - Objective: Firm conclusion about whether short and long-term gout medications use has an impact on cancer risk remain inconclusive. The aim of this study was to investigate the association between gout drugs use and risk of cancer. Methods: We conducted a retrospective longitudinal population-based case-control study in Taiwan. Cases were identified all patients who were aged 20 years or above, and had a first time diagnosis of cancers for the period between 2001 and 2011. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated by using conditional logistic regression. Results: We examined 601,733 cases and 2,406,932 matched controls. The adjusted odd ratio for any gout drugs use and overall cancer risk was 1.007 (95% CI: 0.994–1.020). There was a significant risk of leukemia (AOR: 1.34, 95% CI: 1.20–1.50), endometrial cancer (AOR: 1.33, 95% CI: 1.12–1.57), non-Hodgkin's (AOR: 1.24, 95% CI: 1.13–1.35), female breast cancer (AOR: 1.21, 95% CI: 1.13–1.29), cervical cancer (AOR: 1.21, 95% CI: 1.07–1.37). However, no association was observed in male group (AOR: 0.97, 95% CI: 0.95–0.98) but female showed a significantly increased risk of cancer at any site (AOR: 1.107, 95% CI: 1.08–1.13). Conclusion: In summary, our results suggest that gout drugs increase risk of the most common cancers, particularly in leukemia, non-Hodgkin's, endometrial, breast and cervical cancer.

KW - Allopurinol

KW - Breast cancer

KW - Cervical cancer

KW - Gout drugs

KW - Pharmacoepidemiology etc.

UR - http://www.scopus.com/inward/record.url?scp=85044991890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044991890&partnerID=8YFLogxK

U2 - 10.1016/j.jbspin.2018.01.008

DO - 10.1016/j.jbspin.2018.01.008

M3 - Article

AN - SCOPUS:85044991890

JO - Revue du Rhumatisme (English Edition)

JF - Revue du Rhumatisme (English Edition)

SN - 1169-8446

ER -